1. Home
  2. News
  3. Immutep Ltd
  4. Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC
More Immutep Ltd news
Immutep LtdASX: IMM

Expansion of INSIGHT-003 trial for Efti in 1st Line NSCLC

Mar 29, 2023 at 11:17 PM EDT · Issued by Immutep Ltd

Filed with ASX · Mar 29, 2023 at 11:17 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/expansion-of-insight-003-trial-for-efti-in-1st-line-nsclc

Immutep Ltd on 6ix

Story so far

  • Commercial Scale in Manufacturing of Efti AchievedDec 8, 2022
  • New Patents Granted in Japan and South Korea for EftiNov 9, 2022
  • Fast Track granted by US FDA for Efti in 1st line NSCLCOct 4, 2022

Earlier from Immutep

  • Initiation of Ph 2/3 Trial for Metastatic Breast CancerMar 13, 2023
  • Enrolment Target Reached for INSIGHT-003 Trial in NSCLCFeb 5, 2023
  • TACTI-003 trial 50% enrolment milestone has been achievedJan 3, 2023
  • Update on MBC trial design following successful FDA meetingDec 23, 2022
  • Commercial Scale in Manufacturing of Efti AchievedDec 7, 2022

Later from Immutep

  • Positive Final Data in 2nd Line Metastatic NSCLC PatientsMar 31, 2023
  • Initiation of Phase 2 Trial for Efti in Soft Tissue SarcomaApr 16, 2023
  • Response to ASX Aware QueryApr 18, 2023
  • Immutep to announce new TACTI-002 data at ASCO 2023Apr 26, 2023
  • Approval to start Efti & Bavencio trial in urothelial cancerApr 30, 2023
All Immutep news releases↗

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer